OSI-774: Phase II

In an ongoing Phase II trial of 56 patients with advanced, refractory NSCLC, 150 mg of OSI-774 given

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE